Recall Register

Drug recall: SYMJEPI (epinephrine injection, USP) 0.3 mg, (0.3 mg/0.3 mL), Two Pre-Filled Single-Dose Syringes per carton, Rx Only…

Class I FDA enforcement event 89778. Recall start date: . Status in the FDA record: Terminated. Termination date: .

Reason for recall, in the words of FDA

Defective Delivery System: Potential clogging of the needle preventing the dispensing of epinephrine.

Class I, in the words of FDA

a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death

Adamis Pharmaceuticals Corporation started this drug recall on 21 Mar 2022. The firm address in the FDA record is in San Diego, CA. FDA put the recall in Class I. FDA event 89778 has 2 product records. The first FDA enforcement report date is 13 Apr 2022. The record gives the status Terminated, with the termination date 8 Feb 2023.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Nationwide in the U.S.A.

Recalling firm

Adamis Pharmaceuticals Corporation, San Diego, CA.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

2 product records in the event.

FDA event 89778: product records
Recall numberProductQuantityClassStatusReport date
D-0763-2022SYMJEPI (epinephrine injection, USP) 0.3 mg, (0.3 mg/0.3 mL), Two Pre-Filled Single-Dose Syringes per carton, Rx Only, Manufactured for Adamis Pharmaceuticals Corp.; San Diego, CA 92130; Distributed by USWM, LLC., Louisville, KY 40241, Made in Belgium, NDC 78670-130-0225,103 cartonsClass ITerminated13 Apr 2022
D-0764-2022SYMJEPI (epinephrine injection, USP) 0.15 mg (0.15 mg/0.3 mL), Two Pre-Filled Single-Dose Syringes per carton, Rx Only, Manufactured for Adamis Pharmaceuticals Corp.; San Diego, CA 92130; Distributed by USWM, LLC., Louisville, KY 40241, Made in Belgium, NDC 78670-131-02.2,500 cartonsClass ITerminated13 Apr 2022

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class I: The highest of the three FDA recall classes.

The event in context

Drug events that started in 2022
325
Share of these events in Class I
18%
Product records in this event
2
Events of the firm on the register
1

Official channels

Cite this page

Recall Register. FDA enforcement event 89778. https://recallregister.com/fda/i/89778/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Nationwide in the U.S.A.
What quantity of product is in FDA event 89778?
The event has 2 product records. The first record gives this quantity: 25,103 cartons
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2022 have the same class?
18% of the 325 drug events that started in 2022 are in Class I.